Across TCGA pan-cancer cohorts, LRRC46 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated LRRC46 data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher LRRC46 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LRRC46 expression acts as an unfavorable survival marker.
OV are the cancer types where LRRC46 Mutation most reproducibly stratifies survival.